Altimmune, Inc. (NYSE:ALT)’s stock price rose 1.6% on Wednesday . The stock traded as high as $1.93 and last traded at $1.93, approximately 100 shares were traded during mid-day trading. A decline of 100% from the average daily volume of 716,714 shares. The stock had previously closed at $1.90.

Separately, Roth Capital reaffirmed a “buy” rating on shares of Altimmune in a report on Friday, July 19th.

The firm has a fifty day simple moving average of $2.06 and a two-hundred day simple moving average of $2.44.

Altimmune (NYSE:ALT) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.26) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.01). The company had revenue of $1.63 million during the quarter, compared to the consensus estimate of $2.41 million.

About Altimmune (NYSE:ALT)

Altimmune, Inc, a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials.

Featured Story: What is a Call Option?

Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with's FREE daily email newsletter.